Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Announces Further Management Changes

Published: Wednesday, October 02, 2013
Last Updated: Wednesday, October 02, 2013
Bookmark and Share
Stefan Oschmann to focus on role as Head of Pharmaceuticals in charge of Merck Serono, Consumer Health, Allergopharma and Biosimilars.

Merck today announced multiple management and organizational changes in its pharmaceutical businesses to maximize growth opportunities going forward. Belén Garijo, currently Chief Operating Officer at Merck Serono, the biopharmaceutical division of Merck, has been appointed President and Chief Executive Officer of Merck Serono, effective October 1. She will succeed Stefan Oschmann, who as Member of the Executive Board and Head of Pharmaceuticals at Merck, will focus on further developing the Merck Serono and Consumer Health divisions as well as the Allergopharma and Biosimilars units. All four entities will report to Stefan Oschmann.

“Following our transformational journey over the past two years, we have reached a critical juncture with accelerated profit growth at Merck Serono and a successful re-focusing of our Consumer Health division,” Executive Board Member Stefan Oschmann said. “I’m absolutely convinced that with today’s management and organizational changes we will be able to fully leverage the growth potential in our pharmaceutical businesses by focusing on fast-growing areas such as the emerging markets and the global allergy market or the rapidly evolving biosimilars market. At Merck Serono, we are proud to have in Belén Garijo one of the most successful leading women in our industry, who – with her broad leadership experience spanning medical, strategic, and commercial roles – will be able to take Merck’s largest division to the next level.”

As part of the organizational changes at Merck Serono, the company also appointed Dr. Annalisa Jenkins, MBBS, MRCP, currently Head of Global Development and Medical, as Head of Global Research & Development, effective October 1. Under her leadership, Merck Serono aims to further integrate the two fields as a number of compounds in the division’s pipeline are reaching late-phase development. Following the appointment of Jim Stewart as Chief Information Officer of the Merck Group at the end of last month, Thierry Hulot, Head of the Biosimilars unit, has been named to succeed Jim Stewart as Head of Global Manufacturing & Supply as of October 1. Hulot will continue to lead the Biosimilars unit on an interim basis until a replacement has been announced. All global functions within Merck Serono – including R&D, Manufacturing & Supply, Operations and Business Development – will report to Garijo.

Reflecting the rising importance of Allergopharma and Biosimilars, the two units will report directly to Oschmann. Following the acquisition of the remaining interest in Allergopharma in December 2012, Merck aims to further tap into the global allergy market with a very competitive product range. With its investments in the evolving biosimilars market, the company expects to benefit from rising demand for biotechnology solutions to address unmet medical and access needs in many parts of the world.

Generating total revenues of € 6.4 billion in 2012, Merck Serono is the largest division of Merck. Overall, the pharmaceutical businesses of Merck accounted for around 60% of total revenues and 58% of EBITDA pre one-time items last year.

Page 3 of 4 Dr. Stefan Oschmann, Ph.D., has been a Member of the Executive Board of Merck since January 2011. He is responsible for the Pharmaceuticals businesses including the divisions Merck Serono and Consumer Health as well as Allergopharma and Biosimilars as of October 1. Before joining Merck, he worked for the U.S. company MSD (in North America Merck & Co.), where he served most recently as President of Emerging Markets.

Dr. Belén Garijo, MD, is designated President and Chief Executive Officer for Merck Serono and in her new role will chair the Pharmaceutical Executive Committee as of October 1. She joined the company in 2011, previously serving as Chief Operating Officer. Prior to joining Merck Serono, Dr. Garijo was Senior Vice President, Global Operations Region Europe at Sanofi from 2006, based in Paris, serving as a member of the Management Committee for the Sanofi-Aventis Group, and as a member of the Management Board for the Sanofi-Pasteur vaccines JV with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. Belén Garijo has been an Independent Member of the Board of Directors of Banco Bilbao Vizcaya Argentaria SA (BBVA) since 2012.

Dr. Annalisa Jenkins, MBBS, MRCP, is Executive Vice President, Head of Global Research and Development for Merck Serono. In addition, she leads Global Medical Affairs and Quality and is a member of the Pharmaceutical Executive Committee. She joined the company in 2011, previously serving as Head of Global Development and Medical. Prior to joining Merck Serono, Dr. Jenkins was Senior Vice President, Global Medical Affairs at Bristol-Myers Squibb (BMS). During her tenure at BMS she made significant contributions to the globalization of Medical Affairs, the progression of a number of the key pipeline programs and the execution of a number of strategic transactions. Dr. Jenkins is on the board of Transcelerate Biopharma Inc., the Concert Artists Guild New York and the corporate advisory board of the Center for Talent Innovation. She is also a member of the Scientific Leadership Advisory Council at PhRMA.

Thierry Hulot, Pharma D, MBA, is Senior Vice President, Head of the Biosimilars unit for Merck Serono and designated Head of Global Manufacturing & Supply as of October 1. Thierry Hulot is also a member of the Pharmaceutical Executive Committee. He joined Merck Santé in 1995 as head of Pharmacokinetics and drug metabolism based in Lyon, France and was later appointed team leader for a Phase II program, then Director of Global Early-Stage Projects and Project Management within the Merck Group. During the Merck Serono integration he built the project management function. From 2010, he led Merck Serono’s CEO office until taking on his current role as head of the Biosimilars Unit in 2012.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Joins DiViNe Consortium
The DiViNe project's integrated purification platform will first be tested with diverse, heterogeneous vaccines including glycoconjugates, protein antigens and viruses.
Thursday, September 15, 2016
Phase 3 Studies of Merck's Bezlotoxumab Successful
Company plans to submit new drug applications in U.S., EU and Canada in 2015.
Tuesday, September 22, 2015
Merck and Samsung Bioepis Announce Approval of BRENZYS™
First product from global partnership to deliver high-quality biosimilars to help meet needs of patients and healthcare systems worldwide.
Thursday, September 10, 2015
Polyplus-transfection and Merck Sign License and Supply Agreement
The global prior use license agreement and extended supply agreement covers Polyplus-transfection’s polyethylenimine (PEI) based transfection reagents.
Thursday, October 24, 2013
Scientific News
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos